beta-lapachone has been researched along with Triple Negative Breast Neoplasms in 2 studies
beta-lapachone: antineoplastic inhibitor of reverse transcriptase, DNA topoisomerase, and DNA polymerase
beta-lapachone : A benzochromenone that is 3,4-dihydro-2H-benzo[h]chromene-5,6-dione substituted by geminal methyl groups at position 2. Isolated from Tabebuia avellanedae, it exhibits antineoplastic and anti-inflammatory activities.
Triple Negative Breast Neoplasms: Breast neoplasms that do not express ESTROGEN RECEPTORS; PROGESTERONE RECEPTORS; and do not overexpress the NEU RECEPTOR/HER-2 PROTO-ONCOGENE PROTEIN.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lin, LC | 1 |
| Lee, HT | 1 |
| Chien, PJ | 1 |
| Huang, YH | 1 |
| Chang, MY | 1 |
| Lee, YC | 1 |
| Chang, WW | 1 |
| Cao, L | 1 |
| Li, LS | 1 |
| Spruell, C | 1 |
| Xiao, L | 1 |
| Chakrabarti, G | 1 |
| Bey, EA | 1 |
| Reinicke, KE | 1 |
| Srougi, MC | 1 |
| Moore, Z | 1 |
| Dong, Y | 1 |
| Vo, P | 1 |
| Kabbani, W | 1 |
| Yang, CR | 1 |
| Wang, X | 1 |
| Fattah, F | 1 |
| Morales, JC | 1 |
| Motea, EA | 1 |
| Bornmann, WG | 1 |
| Yordy, JS | 1 |
| Boothman, DA | 1 |
2 other studies available for beta-lapachone and Triple Negative Breast Neoplasms
| Article | Year |
|---|---|
NAD(P)H:quinone oxidoreductase 1 determines radiosensitivity of triple negative breast cancer cells and is controlled by long non-coding RNA NEAT1.
Topics: Cell Line, Tumor; Cell Proliferation; Cell Survival; Female; Gene Expression Regulation, Neoplastic; | 2020 |
Tumor-selective, futile redox cycle-induced bystander effects elicited by NQO1 bioactivatable radiosensitizing drugs in triple-negative breast cancers.
Topics: Animals; Bystander Effect; Female; Humans; Mice; Mice, Nude; NAD(P)H Dehydrogenase (Quinone); Naphth | 2014 |